Malignant Pleural Mesothelioma Epidemiology Forecast 2034
DelveInsight’s ‘Malignant Pleural Mesothelioma (MPM) Overview - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the MPM historical and forecasted epidemiology as well as the MPM epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain),the United Kingdom, and Japan.
Geographies Covered
- The United States
- EU4 (Germany, France, Italy, Spain) and the United Kingdom
- Japan
Study Period: 2021-2034
Malignant Pleural Mesothelioma (MPM) Understanding
Malignant Pleural Mesothelioma (MPM) Overview
Mesothelioma is a rare, aggressive cancer that develops in the lungs, abdomen, or heart lining. Asbestos exposure is the only known cause of malignant mesothelioma. Early symptoms of mesothelioma are similar to those of more common diseases such as pneumonia, the flu, or irritable bowel syndrome. Due to how long mesothelioma takes to develop, symptoms often do not appear until tumors have progressed. Many patients are diagnosed with mesothelioma after exhibiting a persistent cough, pneumonia-like symptoms, or fluid buildup; as this type of cancer can take decades to develop, its symptoms often appear without warning.
The type of mesothelioma can be based on where the tumors develop in the body. Pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, and testicular mesothelioma are the common types and comprise almost all of the cases.
Continued in the report…
Malignant Pleural Mesothelioma (MPM) Diagnosis
The diagnosis of pleural mesothelioma often consists of multiple tests. One or more imaging scans, such as an x-ray or CT scan, may be performed first to identify tumors or metastasis. If a tumor is detected, blood tests may be performed to look for certain biomarkers, which can help differentiate mesothelioma from other conditions. A biopsy only verifies MPM diagnosis. Tests like a thoracentesis or thoracoscopy may be performed to take a tissue or fluid sample for analysis. For a thoracentesis, a doctor typically inserts a fine needle to remove fluid buildup in the chest.
Continued in the report…
Malignant Pleural Mesothelioma (MPM) Epidemiology Perspective by DelveInsight
The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of MPM in Mesothelioma, Gender-specific Incident Cases of MPM, Age-specific Incident Cases of MPM, Histology-specific Incident Cases of MPM, Stage-specific Incident Cases of MPM scenario in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.
Malignant Pleural Mesothelioma (MPM) Detailed Epidemiology Segmentation
- As per DelveInsight’s estimates, in the year 2021, there were ~12,300 incident cases of mesothelioma in the 7MM. The total incident cases of MPM were ~10,800 in the 7MM in 2021.
- The United States, in 2021, accounted for ~17% of the total MPM cases in the 7MM. There were ~1,900 cases of MPM in the US in 2021.
- In the 7MM, the total gender-specific cases of MPM were ~8,500 cases for males and ~2,400 cases for females in the year 2021.
- In the 7MM, maximum number of MPM cases were in the age category of 70-79 years. There were approximately 4000 MPM cases lying in the age bracket of 70-79 years in 2021 in the 7MM countries.
- In the 7MM, the total type-specific cases of MPM were ~4,400, ~860, ~880, and ~4,700 cases for Epithelioid, Biphasic, Sarcomatous, and Mesothelioma NOS/NA types in 2021.
- As per the estimates, in the 7MM, the total stage-specific cases of MPM were ~1,200, ~1,700, ~6,400, and ~1,500 cases for Localized, Regional, Distant, and Unknown stages in 2021.
Get a more detailed overview of How the Malignant Pleural Mesothelioma Market will evolve by 2034: Malignant Pleural Mesothelioma Market Outlook and Forecast
Scope of the Report
- The report covers a descriptive overview of MPM, explaining its associated indications, and currently available therapies.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan.
- The report assesses the MPM risk and burden.
- The report provides the segmentation of the epidemiology for 7MM by segmented by ‘Total Incident Cases of MPM in Mesothelioma, Gender-specific Incident Cases of MPM, Age-specific Incident Cases of MPM, Histology-specific Incident Cases of MPM, Stage-specific Incident Cases of MPM’.
Report Highlights
- 10-year forecast of MPM
- 7MM Coverage
- Total Incident Cases of MPM in Mesothelioma Indication-specific Cases of MPM
- Gender-specific Incident Cases of MPM
- Age-specific Incident Cases of MPM
- Histology-specific Incident Cases of MPM
- Stage-specific Incident Cases of MPM
Key Questions Answered
- What are the risk, burdens, and unmet needs of MPM?
- What is the historical MPM patient pool in the United States, EU4 (Germany, France, Italy, Spain), the UK, and Japan?
- What would be the forecasted patient pool of MPM at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MPM?
- Out of the countries mentioned above, which country would have the highest cases of MPM during the forecast period (2025-2034)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?
Reasons to buy
The MPM report will allow the user to -
- Develop business strategies by understanding the trends, shaping and driving the 7MM MPM epidemiology.
- The MPM epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
- The MPM epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
